Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
Rhea-AI Summary
Clearmind Medicine (Nasdaq: CMND) announced on March 30, 2026 the successful completion of treatment and follow-up for 18 participants in its FDA‑approved Phase I/IIa trial of CMND-100, a non‑hallucinogenic MEAI‑based oral candidate for Alcohol Use Disorder.
The company also treated four additional participants at its Tel Aviv site, and the multinational trial includes sites at Yale, Johns Hopkins, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.
Positive
- Completed treatment and follow-up for 18 participants
- Enrollment expanded with 4 additional Tel Aviv participants
- Trial is FDA‑approved Phase I/IIa for CMND-100
- Multinational, multicenter sites including Yale and Johns Hopkins
Negative
- No efficacy or quantitative outcome data disclosed for the 18 participants
- Completed cohort of 18 participants remains small for definitive conclusions
News Market Reaction – CMND
In the Mar 30 session, CMND gained 22.70%, reflecting a significant positive market reaction. Argus tracked a peak move of +28.1% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 19 | Clinical trial update | Positive | -3.1% | Ongoing successful treatment at U.S. sites with no serious adverse events. |
| Mar 11 | Clinical recruitment | Positive | -6.3% | Advancing recruitment for Cohort 3 after positive topline results and DSMB approval. |
| Mar 04 | DSMB clearance | Positive | -4.8% | Data Safety Board cleared progression to next CMND-100 dose cohort after review. |
| Feb 09 | Safety results | Positive | -8.2% | Additional positive topline safety data from second cohort with good tolerability. |
| Jan 14 | Cohort completion | Positive | +0.4% | Completion of treatment in all six patients of the second CMND-100 cohort. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical trial updates for CMND-100 have generally been positive operationally but followed by weak price reactions: 4 of the last 5 similar announcements saw negative next-day moves, with an average move of -4.39%.
Over recent months, Clearmind has steadily advanced its FDA-approved Phase I/IIa CMND-100 trial for Alcohol Use Disorder, progressing from completion of the second cohort and favorable safety data to DSMB clearance and Cohort 3 enrollment at sites including Yale, Johns Hopkins, and Tel Aviv centers. Despite these clinically positive milestones, shares typically reacted negatively after such updates, with several clinical trial headlines in Jan–Mar 2026 followed by next-day declines, highlighting a history of weak price follow-through on good trial news.
Key Terms
phase i/iia clinical trial medical
alcohol use disorder medical
pharmacokinetics medical
tolerability medical
fda-approved regulatory
neuroplastogen-derived therapeutics medical
meai-based oral drug candidate medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company completed treatment in four additional participate at its Israel clinical site
Vancouver, Canada, March 30, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment and follow-up of 18 participants in its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).
This milestone reflects continued positive progress and strong momentum in the multinational, multicenter study, which is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD.
The Company also wishes to announce that four additional participants have been successfully treated at the clinical center in Tel Aviv, further expanding enrollment and demonstrating the operational strength of the Israeli sites in the trial.
“We are very encouraged by the successful completion of treatment and follow-up for these 18 participants, alongside the rapid addition of four more patients at our Tel Aviv center,” said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. “This steady progress across our sites underscores the favorable safety and tolerability profile of CMND-100 and brings us closer to potentially delivering a much-needed innovative therapy for Alcohol Use Disorder.”
The Phase I/IIa clinical trial is being conducted at leading institutions, including Yale University, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND."
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing and progress of its clinical trials and potentially delivering a much-needed innovative therapy for Alcohol Use Disorder. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
